Autres langues PTC Therapeutics, Inc.

Actions

PTCT

US69366J2006

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
33,62 ^USD	-1,58 %		+31,89 %	+21,99 %

29/04	PTC THERAPEUTICS, INC. : Morgan Stanley n'est plus vendeur	ZM
26/04	Mise à jour sectorielle : Les actions du secteur de la santé sont en hausse en fin d'après-midi	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

PTC Therapeutics to Participate at Upcoming Investor Conferences	02/05
North American Morning Briefing : More Earnings -2-	30/04
Sector Update: Health Care Stocks Edge Higher Late Afternoon	26/04
Sector Update: Health Care	26/04
PTC Therapeutics Shares Rise After Better-Than-Expected Q1 Results	26/04
PTC Therapeutics : Q1 2024 FLS	25/04
PTC Therapeutics: Q1 Earnings Snapshot	25/04
Earnings Flash (PTCT) PTC THERAPEUTICS Posts Q1 Revenue $210.1M, vs. Street Est of $163.8M	25/04
PTC Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	25/04
PTC Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2024	25/04
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	24/04
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23/04
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results	12/04
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results	11/04
PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment	28/03
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	28/03
PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	28/03
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency	20/03
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza? as a Treatment for AADC Deficiency	19/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues PTC Therapeutics, Inc.

Actions

PTCT

US69366J2006

Autres langues

Filtres